Spencer Duncan, DO
Family Medicine · Valley Center, KSNPI 1497934061
Payments from drug & device makers
Across 357 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$971
- Novo Nordisk$780
- Lilly USA, LLC$558
- Pfizer$404
- GSK$328
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$271
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,490100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $971 |
| Novo Nordisk | 57 | $780 |
| Lilly USA, LLC | 41 | $558 |
| Pfizer | 41 | $404 |
| GSK | 24 | $328 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $271 |
| AbbVie(2 entities) | 16 | $263 |
| Abbott | 13 | $243 |
| Amarin Pharma, Inc. | 10 | $185 |
| Amgen | 10 | $173 |
| Johnson & Johnson | 11 | $157 |
| Boehringer Ingelheim | 10 | $155 |
| Merck | 7 | $103 |
| E.r. Squibb & Sons, L.L.C. | 3 | $87 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Sanofi Pasteur Inc. | 4 | $78 |
| Bayer | 5 | $73 |
| Sumitomo Pharma America, Inc. | 4 | $70 |
| Astellas Pharma US Inc | 4 | $64 |
| Eisai Inc. | 3 | $58 |
| Exact Sciences | 3 | $46 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $42 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Medtronic | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Novartis | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Apria Healthcare LLC | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,490 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $67,132 |
| EliquisApixaban | 53 | $48,659 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $42,841 |
| XareltoRivaroxaban | 32 | $30,155 |
| JardianceEmpagliflozin | 27 | $27,129 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $19,984 |
| MounjaroTirzepatide | 19 | $19,343 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $15,606 |
| JanuviaSitagliptin Phosphate | 14 | $14,300 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $12,975 |
| FarxigaDapagliflozin Propanediol | 21 | $11,015 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,556 |
| Gabapentin | 212 | $3,559 |
| Potassium Chloride | 125 | $3,414 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 203 | $2,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $780 | $67,13270 claims |
| PfizerEliquis | $404 | $48,65953 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $971 | $30,99943 claims |
| Johnson & JohnsonXarelto | $157 | $30,15532 claims |
| Boehringer IngelheimJardiance | $155 | $27,12927 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $328 | $23,16233 claims |
| Lilly USA, LLCMounjaro | $558 | $19,34319 claims |
| MerckJanuvia | $103 | $14,30014 claims |
| AbbVieSynthroid | $263 | $99323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Valley Center
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.